CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers

Cancer Biology and Therapy

Volumn 10, Issue 6, 2010, Pages 615-616

  Brody, Jonathan R ^a   Witkiewicz, Agnieszka K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast cancer; CXCR4; ER negative; Heterogeneity; ITF2; MDA MB 231 cells; Microarray

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ITF2 PROTEIN; PROTEIN; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; DISEASE FREE SURVIVAL; EPIGENETICS; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROARRAY ANALYSIS; NOTE; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 77957171073     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.6.12906     Document Type: Note

References (17)

1. Appaiah H. ITF2 is a target of CXCR4 in MDA-MB-231 Breast Cancer Cells and is Associated with Reduced Survival in Estrogen-negative Breast Cancer. Cancer Biol Ther 2010; This issue.
2. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382:635-8. (Pubitemid 26268957)
3. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006; 238:30-41.
4. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6.
5. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009; 14:1182-8.
6. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 2010; 29:16.
7. Mizell J, Smith M, Li BD, Ampil F, Chu QD. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. Annals of surgical oncology 2009; 16:2711-6.
8. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64:8604-12. (Pubitemid 39552073)
9. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65:967-71.
10. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-49. (Pubitemid 36808649)
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
12. Meng Y, Gu C, Wu Z, Zhao Y, Si Y, Fu X, Han W. Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors. BMC Cancer 2009; 9:75.
13. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2009; In press.
14. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-601.
15. de Candia P, Benera R, Solit DB. A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res 2004; 92:81-94. (Pubitemid 39458113)
16. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev 2004; 4:901-9.
17. Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP, Liotta DC. Discovery of small molecule CXCR4 antagonists. J Med Chem 2007; 50:5655-64.